AgelessRx Review: Some of the Cheapest Brand-Name GLP-1 Pricing We've Found — And a Flagship Drug With No Human Longevity Evidence

What Is AgelessRx?

AgelessRx, Inc. operates from Ann Arbor, Michigan, with a BBB start date of 11 October 2019. It positions itself as a longevity medicine practice rather than a weight-loss funnel, and unusually for this market it has the substance to back some of that positioning: it is one of forty global semi-finalists in the XPRIZE Healthspan competition, it publishes a research section, and it states that more than 5,200 participants have completed clinical studies on its therapies.

It also does something we have asked for repeatedly across this series and almost never seen. When it claims '82.7% of patients reported one or more improvements by their first check-in', it appends the methodology: the data was self-reported by 7,084 surveyed customers who checked in between 21 January and 8 April 2024, all of whom had been approved for a prescription after a provider assessment, with the note that actual results may vary. That is how a customer statistic should be presented. Several companies in this series quote figures with no source at all.

The catalogue splits into three parts. Conventional approved medicines used off-label for longevity: low dose naltrexone at $25 a month, metformin at $25, rapamycin at $65, plus atorvastatin and telmisartan at $30 and trazodone at $33. Supplement-style interventions: NAD+ by injection at $79, nasal spray at $125, patches at $150 and face cream at $95. And weight management: injectable GLP-1s from $139, microdosing semaglutide at $99 and tirzepatide at $159, brand-name Wegovy at $264 injection or $199 in pill form, and Zepbound at $364.

Alongside these sit diagnostics: a PhenoAge blood test at $75, a Core Longevity Panel at $95, a TruMe saliva epigenetic test at $170 and the Galleri multi-cancer detection test at $949.

The brand-name GLP-1 pricing is the standout bargain and deserves flagging early. Wegovy at $264 and Zepbound at $364 are dramatically below the $899 to $1,399 we have documented at other providers, and reflect manufacturer direct-pay programmes now available. If you want FDA-approved weight-loss medication and are paying cash, that is among the best pricing in this entire series.

Treatments, Tests & What They Cost

Two things stand out in this table. The brand-name GLP-1 prices are genuinely excellent — Wegovy at $264 and Zepbound at $364 against the $899 to $1,399 we have found elsewhere, reflecting manufacturer direct-pay programmes rather than any AgelessRx discount, but passed on rather than marked up. If you want FDA-approved medication and are paying cash, start here. The other is how cheap the conventional off-label drugs are: LDN and metformin at $25 and rapamycin at $65 are generic medicines at generic prices, which is honest pricing for what they are. The compounded NAD+ line at $79 to $150 is where the value case is weakest, and the $949 Galleri test is a substantial outlay for something we discuss below.

Approved, Off-Label and Experimental — What You're Actually Taking

The regulatory picture here is more varied than most providers in this series, and worth separating carefully.

Several products are ordinary approved medicines. Metformin, atorvastatin, telmisartan and trazodone are all FDA-approved drugs, and prescribing them is routine medicine — though prescribing metformin specifically to slow ageing rather than to treat diabetes is off-label, and the trial designed to test that idea, TAME, has struggled for years to secure funding. Wegovy and Zepbound are FDA-approved for weight management and are the actual branded products.

Low dose naltrexone is off-label use of an approved drug. Naltrexone is approved at 50mg for opioid and alcohol dependence; LDN typically means 1.5 to 4.5mg, used for chronic pain and autoimmune conditions. There is some genuine trial evidence — small studies in fibromyalgia and Crohn's disease — but it is a long way from established therapy, and it is not approved for anything at that dose.

Rapamycin is the one that needs a proper explanation, because it is the flagship of longevity medicine and it is not a benign supplement. Sirolimus has exactly two FDA-approved indications: prophylaxis of organ rejection in kidney transplantation, given with cyclosporine and corticosteroids, and lymphangioleiomyomatosis. It works by preventing activation of T-cells and B-cells through inhibition of their response to interleukin-2. In plain terms, it is an immunosuppressant.

The longevity interest is real and not fringe. Rapamycin extends lifespan in mice — one of the most robust findings in geroscience — and inhibition of the mTOR pathway is a serious hypothesis about ageing. What does not exist is any human trial showing it extends lifespan or healthspan in people. Taking it for longevity is participating in an experiment, not receiving a treatment.

On risk, be fair about dose. In kidney transplant patients on 5mg daily, rapamycin was associated with substantially higher rates of hypercholesterolaemia (46% versus 23% on placebo), hyperlipidaemia (57% versus 23%), thrombocytopenia (30% versus 9%), anaemia (33% versus 21%), rash, arthralgia and diarrhoea, and nephrotoxicity is now recognised despite early expectations otherwise. Longevity protocols use far lower, intermittent dosing — typically a single weekly dose — so those figures overstate the risk considerably at the doses AgelessRx would prescribe. But the drug is still an immunosuppressant, chronic use carries risks of infection and pulmonary toxicity, and the long-term safety of weekly dosing in healthy people has not been established because nobody has run that trial.

The NAD+ products are compounded and not FDA-approved. The FDA has separately warned that compounders have used food-grade NAD+ to make injectable products, cautioning that food-grade ingredients are not suitable for sterile compounding without appropriate processing.

And the microdosing GLP-1 line carries the caveat we have raised elsewhere: no clinical trial has tested sub-therapeutic GLP-1 regimens. Every efficacy figure comes from trials that titrated to specific maintenance doses.

The Consultation Process

Eligibility

• •Adults, following assessment by a licensed medical provider. AgelessRx states it will set up a visit to evaluate whether you are an appropriate candidate for any prescription product.
• •Rapamycin should not be taken by anyone who is immunocompromised, has an active infection, or is due to have surgery — it impairs wound healing and suppresses immune function. Discuss vaccination timing with the prescriber, since live vaccines are contraindicated with immunosuppressants.
• •Rapamycin can raise cholesterol and triglycerides, lower platelet and red cell counts, and affect kidney function. If you take it, insist on periodic bloodwork — lipids, full blood count and renal function at minimum.
• •Metformin requires renal function awareness and can cause B12 deficiency with long-term use. It is contraindicated in significant renal impairment.
• •Low dose naltrexone must not be taken by anyone using opioids — even at low doses naltrexone can precipitate withdrawal, and it will block opioid analgesia if you need pain relief after an accident or surgery. Tell any treating clinician you take it.
• •GLP-1 medicines are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must not be used in pregnancy.
• •Trazodone carries the antidepressant class warning regarding suicidal thoughts in younger adults and can cause priapism, a urological emergency.
• •Do not use any of these in pregnancy or while breastfeeding without specific clinical advice.
• •If you are already under a clinician's care for any condition, tell them what you are taking. Rapamycin in particular is not a supplement and other doctors need to know about it.

Clinicians, Testing & Pharmacy

Shipping & Support Services

Medication ships to patients. The complaint record includes a package left outside that arrived hot, and repeated NAD+ shipment problems — worth planning around for temperature-sensitive products.

• •Publishes a price for every treatment and every test
• •Discloses the methodology behind its customer statistics — sample size, dates and self-reported status
• •XPRIZE Healthspan semi-finalist, one of forty teams globally
• •Brand-name Wegovy at $264 and Zepbound at $364 — among the cheapest cash pricing we have found
• •Cheap generics honestly priced: LDN and metformin at $25, rapamycin at $65
• •Offers real biomarker testing from $75, not just drugs
• •Organises by health need as well as by product
• •Publishes a research section and a named medical team
• •Trading since October 2019
• •Prescribes approved medicines used off-label rather than only compounded products

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who AgelessRx May Be Best For

• •Anyone paying cash for a brand-name GLP-1 — the Wegovy and Zepbound pricing here is exceptional
• •People who want approved generics like metformin or LDN prescribed cheaply and openly
• •Buyers who want baseline biomarker testing alongside any intervention
• •Anyone drawn to longevity medicine who wants a provider that publishes research and discloses its methodology
• •People who understand rapamycin is experimental and want it prescribed with monitoring rather than sourced grey-market

Limitations

• •Take the good part first, because it is genuinely good. Wegovy at $264 a month and Zepbound at $364 are the cheapest brand-name GLP-1 prices we have found across this entire series — roughly a quarter of what some competitors charge for the identical FDA-approved product. That reflects manufacturer direct-pay programmes rather than anything AgelessRx invented, but passing the saving through rather than marking it up is the right thing to do, and if you are paying cash for weight-loss medication this is where to start. It also makes the compounded and microdosed alternatives on the same site harder to justify.
• •The disclosure standard is the other thing worth praising specifically. When AgelessRx says 82.7% of patients reported improvements, it tells you the number was self-reported, by whom, how many, and over what period. Across seventy-odd reviews this month we have seen companies claim 100,000 patients four months after launch and quote outcome figures with no source at all. This is what the alternative looks like.
• •Rapamycin is where a buyer needs to think hardest. The science is real and serious — it extends lifespan in mice reliably, and mTOR inhibition is a legitimate hypothesis about ageing. But sirolimus is approved for exactly two things, kidney transplant rejection and lymphangioleiomyomatosis, and it works by suppressing T-cell and B-cell activation. No human trial has shown it extends lifespan or healthspan. Longevity dosing is far lower and less frequent than the transplant dosing that generated the well-documented adverse effects, which genuinely reduces the risk — but 'lower dose of an immunosuppressant, long-term, in healthy people, never formally studied' is an experiment, and it should be entered as one. If you take it, insist on lipid panels, blood counts and renal function monitoring, tell every other clinician you see, and ask what would make them stop.
• •The service record is the practical reservation. A D- rating from two unanswered complaints is a small sample producing a bad grade, and we would not overweight two complaints against a company of this size. But what those complaints describe — medication left outside arriving hot, repeated NAD+ shipment failures, communication breakdowns between provider and pharmacy — matters more for temperature-sensitive injectables than it would for most products. And a company that does not answer complaints is a company you cannot rely on to fix a problem.
• •Two smaller cautions. Microdosing GLP-1s are sold here at $99 and $159, and no trial has tested sub-therapeutic GLP-1 regimens — particularly odd when the same site sells the actual approved product at $264. And the Galleri test at $949 is a multi-cancer early detection test that is not FDA-approved; it is a laboratory-developed test, its performance varies substantially by cancer type, and both false positives and false negatives carry real consequences. That is a conversation to have with a clinician before spending, not after.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

AgelessRx is one of the more credible companies in this series, and two things demonstrate it. Its brand-name GLP-1 pricing — Wegovy at $264 a month, Zepbound at $364 — is roughly a quarter of what several competitors charge for identical FDA-approved medication, and it passes that saving through rather than pocketing it. And when it quotes a customer statistic, it publishes the methodology: self-reported, 7,084 respondents, specific date range. After documenting companies claiming a hundred thousand patients four months after launch, that is what good practice looks like.

It is also a real longevity practice rather than a storefront: an XPRIZE Healthspan semi-finalist, with published research, a named medical team, and biomarker testing from $75 so you can measure something rather than only swallow something.

Rapamycin is where buyers need to be clear-eyed. The science behind it is legitimate — it extends lifespan in mice reliably and mTOR inhibition is a serious hypothesis — but sirolimus is an immunosuppressant approved only for kidney transplant patients and lymphangioleiomyomatosis, and no human trial has shown it extends anyone's life. Longevity dosing is far lower than transplant dosing, which genuinely reduces the risk, but nobody has formally studied weekly rapamycin in healthy people over the long term. That is an experiment, and it should be entered knowingly, with bloodwork.

The service record is the practical concern. A D- from two unanswered complaints is a harsh grade from a small sample, and we would not overread it — but those complaints describe medication left outside arriving hot and repeated shipment failures, which matters more for temperature-sensitive injectables than for most products, and a company that does not reply is one you cannot count on when something goes wrong.

We rate AgelessRx 3.6 out of 5 — exceptional GLP-1 value and an unusually honest approach to its own data, alongside a longevity catalogue whose flagship drug is experimental and a complaint record it has not answered.

If you want brand-name weight-loss medication and are paying cash, this is among the best prices anywhere and worth the call. If you want rapamycin, this is a more responsible route than sourcing it grey-market — but go in understanding what it is, insist on monitoring, and tell your other doctors. And skip the microdosed GLP-1s: the real thing is on the same page for barely more money.

This review is informational only and is not medical advice. Rapamycin, metformin and low dose naltrexone are prescribed off-label here; compounded NAD+ and GLP-1s are not FDA-approved. Speak to a licensed clinician before starting, changing or stopping any medication.